Neffy Fails to Secure New Commercial Insurer Coverage, ARS Pharma Shares Plunge 23%
SPRY sits 20% above its 52-week low of $6.66.
Summary
ARS Pharmaceuticals shares plunged 23% after the company announced its key product, Neffy, failed to secure new commercial insurer coverage in the current cycle. This is a significant commercial setback for Neffy, which had seen positive regulatory approvals and initial revenue reports earlier this year. The lack of broad commercial coverage severely limits Neffy's market penetration and revenue potential. In response, ARS Pharma cut its full-year cash-based operating expenses to $248 million and reaffirmed its 2027 cashflow breakeven target. Future updates on commercial formulary additions will be critical.
At the time of this announcement, SPRY was trading at $8.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $6.66 to $18.90. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.